Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CTXR Stock Forecast 2026-2027
$0.54
Current Price
$14.82M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CTXR Price Targets
+640.7%
To High Target of $4.00
+640.7%
To Median Target of $4.00
+640.7%
To Low Target of $4.00
CTXR Price Momentum
-3.6%
1 Week Change
-16.9%
1 Month Change
-38.6%
1 Year Change
-30.8%
Year-to-Date Change
-78.2%
From 52W High of $2.48
+13.4%
From 52W Low of $0.48
📊 TOP ANALYST CALLS
Did CTXR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Citius Pharmaceuticals is one of their latest high-conviction picks.
Latest CTXR Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, CTXR has a bullish consensus with a median price target of $4.00 (ranging from $4.00 to $4.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $0.54, the median forecast implies a 640.7% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Swayampakula Ramakanth at HC Wainwright & Co., projecting a 640.7% upside. Conversely, the most conservative target is provided by Swayampakula Ramakanth at HC Wainwright & Co., suggesting a 640.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CTXR Analyst Ratings
1
Buy
0
Hold
0
Sell
CTXR Price Target Range
Low
$4.00
Average
$4.00
High
$4.00
Current: $0.54
Latest CTXR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CTXR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Assumes | $4.00 |
| Mar 11, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Dec 4, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Aug 13, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jun 30, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jun 10, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jun 9, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| May 23, 2025 | Maxim Group | Hold | Downgrade | $N/A | |
| May 15, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Feb 18, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jan 7, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Dec 30, 2024 | D. Boral Capital | Buy | Upgrade | $N/A | |
| Nov 22, 2024 | D. Boral Capital | Hold | Downgrade | $N/A | |
| Nov 12, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 11, 2024 | D. Boral Capital | Buy | Maintains | $N/A | |
| Aug 19, 2024 | EF Hutton | Buy | Maintains | $N/A | |
| Aug 8, 2024 | EF Hutton | Buy | Maintains | $N/A | |
| Aug 5, 2024 | EF Hutton | Buy | Maintains | $N/A | |
| Jul 15, 2024 | EF Hutton | Buy | Initiates | $N/A | |
| May 31, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Citius Pharmaceuticals, Inc. (CTXR) Competitors
The following stocks are similar to Citius Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Citius Pharmaceuticals, Inc. (CTXR) Financial Data
Citius Pharmaceuticals, Inc. has a market capitalization of $14.82M with a P/E ratio of -0.2x. The company generates $5.61M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -57.7% quarter-over-quarter, while maintaining an operating margin of -1,827.8% and return on equity of -83.6%.
Valuation Metrics
Market Cap
$14.82M
Enterprise Value
$19.48M
P/E Ratio
-0.2x
PEG Ratio
0.0x
Price/Sales
2.8x
Growth & Margins
Revenue Growth (YoY)
-57.7%
Gross Margin
+80.3%
Operating Margin
-1,827.8%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+30.9%
Current Ratio
0.6x
Debt/Equity
1.2x
ROE
-83.6%
ROA
-27.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Citius Pharmaceuticals, Inc. (CTXR) Business Model
About Citius Pharmaceuticals, Inc.
What They Do
Develops innovative critical care biopharmaceuticals.
Business Model
Citius Pharmaceuticals operates as a late-stage biopharmaceutical company, focusing on the development and commercialization of first-in-class therapies in critical care and oncology. The company generates revenue by advancing its product pipeline through clinical development to market launch, targeting serious medical conditions with unmet healthcare needs.
Additional Information
The company is headquartered in Cranford, New Jersey, and emphasizes innovative therapies in areas such as anti-infectives and stem cell therapy. Citius Pharmaceuticals aims to enhance patient outcomes by addressing critical healthcare challenges through its diverse pipeline of candidates.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
23
CEO
Mr. Leonard L. Mazur
Country
United States
IPO Year
2017
Website
citiuspharma.comCitius Pharmaceuticals, Inc. (CTXR) Latest News & Analysis
Latest News
Quick Summary
Citius Oncology presented Phase 1 data at ASCO 2026 showing 48% of evaluated patients with recurrent gynecologic cancers achieved clinical benefit, with a median progression-free survival of 20.5 months.
Why It Matters
Positive clinical data on LYMPHIR in tough-to-treat patients may boost Citius Oncology's stock, indicating potential market value and interest for treatment in gynecologic cancers.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Citius Oncology announced a 24% objective response rate and a 21.1-month average duration of response for LYMPHIR in combination with pembrolizumab. Results will be presented at ASCO 2026.
Why It Matters
The promising data on LYMPHIR's response rate and safety in combination with pembrolizumab may enhance its market potential, influencing stock performance for Citius Oncology and related investments.
Source: PRNewsWire
Market Sentiment:
Neutral
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
29 days ago
Quick Summary
Citius Oncology reported $5.6 million in net revenue for H1 FY 2026, secured $36.5 million in debt and equity, and established broad payer coverage with 83% of target accounts on formulary or under review.
Why It Matters
Citius Oncology's strong revenue growth, secured funding, and broad payer coverage indicate positive market acceptance and financial stability, potentially enhancing investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Citius Pharmaceuticals reported $5.6M in net revenue for H1 FY 2026, raised $5M in a direct offering, and secured up to $36.5M in financing. Payer coverage for LYMPHIR is near 100%.
Why It Matters
Citius Pharma's strong revenue growth and successful financing efforts signal robust business development, enhancing investor confidence in its market potential and financial stability.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Citius Oncology has begun international distribution of LYMPHIR™ (denileukin diftitox-cxdl) to Europe, enhancing patient access following its U.S. launch.
Why It Matters
Citius Oncology's expansion of LYMPHIR™ to international markets enhances growth potential, increases revenue streams, and improves patient access, which could positively impact stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Citius Pharmaceuticals (NASDAQ:CTXR) shares fell after the company announced a registered direct offering, raising concerns over potential dilution among investors.
Why It Matters
Citius Pharmaceuticals' direct offering raises dilution fears, leading to a share price drop. Such financing moves can signal financial instability, impacting investor confidence and future valuations.
Source: Benzinga
Market Sentiment:
Negative
Frequently Asked Questions About CTXR Stock
What is Citius Pharmaceuticals, Inc.'s (CTXR) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Citius Pharmaceuticals, Inc. (CTXR) has a median price target of $4.00. The highest price target is $4.00 and the lowest is $4.00.
Is CTXR stock a good investment in 2026?
According to current analyst ratings, CTXR has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.54. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CTXR stock?
Wall Street analysts predict CTXR stock could reach $4.00 in the next 12 months. This represents a 640.7% increase from the current price of $0.54. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Citius Pharmaceuticals, Inc.'s business model?
Citius Pharmaceuticals operates as a late-stage biopharmaceutical company, focusing on the development and commercialization of first-in-class therapies in critical care and oncology. The company generates revenue by advancing its product pipeline through clinical development to market launch, targeting serious medical conditions with unmet healthcare needs.
What is the highest forecasted price for CTXR Citius Pharmaceuticals, Inc.?
The highest price target for CTXR is $4.00 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a 640.7% increase from the current price of $0.54.
What is the lowest forecasted price for CTXR Citius Pharmaceuticals, Inc.?
The lowest price target for CTXR is $4.00 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a 640.7% increase from the current price of $0.54.
What is the overall CTXR consensus from analysts for Citius Pharmaceuticals, Inc.?
The overall analyst consensus for CTXR is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are CTXR stock price projections?
Stock price projections, including those for Citius Pharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 13, 2026 5:46 PM UTC